Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2025-08-13 00:00:00 ET · period of report 2025-08-11 · accession 0001415889-25-021692 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-08-13 | 2025-08-11+ | LYEL | Lee Gary K. | CSO | S - Sale | $10.43 | -267 | 9,093 | -3% | -$2,786 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-12 | S | D | 136 | $10.34 | 8,957 | D | — | — | (F5) Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. (F6) The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. (F7) On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. |
| 2 | Common | Common Stock | 2025-08-11 | S | D | 131 | $10.53 | 9,093 | D | — | — | (F1) Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. (F2) The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. (F3) Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. (F4) On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. |